INTRODUCTION
Symptomatic severe aortic stenosis (AS) is a progressive disease with a poor prognosis if surgical intervention is not performed [1] . Conventional surgical aortic valve replacement (AVR) through median sternotomy under cardiopulmonary bypass is the treatment of choice [2] . However, the number of high-risk elderly patients has been increasing, with the aging of the population and increase in those who do not want to have their chest opened [3] . Recently, transcatheter aortic valve implantation (TAVI) was introduced and became an attractive alternative therapy in these patients. In TAVI, a bioprosthetic valve is introduced percutaneously through a catheter, usually via the femoral artery, or less often, via the left ventricular apex (transapical approach) through thoracotomy.
Furthermore, significant improvement of survival and quality
Results of Transcatheter vs. Surgical AVR − 347 − of life after TAVI has been reported [4] , and now there is a trend toward performing TAVI in healthier patients [5] .
Although surgical AVR with excellent outcomes has been reported in aged and high-risk patients [6] , the high risk of developing a complete AV block requiring permanent pacemaker implantation, paravalvular leakage that can negatively affect survival, and high costs are still problems associated with TAVI [7] . Therefore, we aimed to compare the early outcomes of conventional AVR and TAVI in high-risk severe AS patients. Surgical AVR was performed through median sternotomy, under cardiopulmonary bypass and mild hypothermia, and concomitant valvular, coronary, or aortic surgery was performed in 25 patients (Table 1) . TAVI procedures were performed with AccuTrak (The CoreValve system; Medtronic, Values are presented as mean±standard deviation or number (%). AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; eGFR, estimated glomerular filtration rate; RVP, right ventricular pressure; NYHA Fc, New York Heart Association functional classification.
METHODS
using the t-test, and categorical variables were compared using the chi-square test or Fisher's exact test. Survival was evaluated with the Kaplan-Meier method, and the log-rank test was used to compare the groups. All statistical analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

1) Patient characteristics
The patient characteristics of the AVR group and TAVI group are summarized in 
2) Operative data
Nineteen patients in the AVR group underwent isolated AVR, and 25 patients underwent AVR with a concomitant valvular, coronary, or aortic procedure. Coronary artery bypass grafting (CABG) was most frequently performed concomitantly with AVR. The operation time was significantly longer in the AVR group (Table 1) .
3) Clinical outcomes
The clinical outcomes are summarized in Values are presented as mean±standard deviation or number (%). Mortality cases were excluded. AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation. group], p=0.014). The causes of readmission other than heart failure aggravation were general weakness (n=2) and aggravation of renal failure (n=1) in the AVR group, and pressure sore management (n=2) in the TAVI group.
Echocardiographic outcomes from the survivors are summarized in Table 4 . The TAVI group had more moderate and severe paravalvular leakage at the first and last follow-up echocardiography. A complete AV block requiring pacemaker implantation developed in 3 patients (2 patients in the AVR group, and 1 patient in the TAVI group) without a significant difference between the two groups.
DISCUSSION
The prognosis in patients with symptomatic severe AS is poor if treated medically [1, 8, 9] . After symptom onset, the 1-year mortality rate in patients with severe AS and without surgical AVR is around 30%, and surgical AVR is the treatment of choice for patients with symptomatic severe AS [1, 9] . However, the risk of surgical mortality increases significantly with age and other comorbid conditions [10] [11] [12] .
Therefore, the TAVI procedure is becoming an alternative therapeutic option in elderly patients with high risks, and with proven safety and efficacy, more patients aged over 80 years who would have been candidates for surgical AVR are now undergoing TAVI [3, [13] [14] [15] .
The Placement of Aortic Transcatheter Valves (PARTNER)
trial is a randomized trial to evaluate TAVI in humans. In PARTNER trial B, 358 patients who were considered inoperable were randomly assigned to TAVI or standard therapy. TAVI significantly reduced mortality from all causes and cardiac symptoms. However, major stroke and vascular complications were more common in TAVI [4] .
In PARTNER trial A, the results of isolated AVR and TAVI were compared in high-risk patients. Six hundred and ninety-nine patients were randomly assigned to AVR or TAVI. There was no significant difference in mortality (1-year mortality rate: 26.8% vs. 24.2%). Major bleeding and new-onset atrial fibrillation were more common in the AVR group. In addition, vascular complications and major stoke were more common in the TAVI group. There was no significant difference in NYHA Fc at 1 year. More than moderate AR due to paravalvular leakage was more common in the TAVI group [16] .
In this study, the TAVI group had a similar 1-year survival to the AVR group despite the fact that TAVI was performed in older and higher risk patients. In addition, the TAVI group Previous publications have reported that the 30-day mortality rate after TAVI ranges from 3.2% to 15.2% [4, [13] [14] [15] [16] . In this study, the early mortality in the TAVI group was 0.0%, and the rate of complete heart block was also lower than in previous reports. These low rates of mortality and complications may have been achieved due to meticulous preoperative evaluation and careful patient selection by a team approach (cardiologist, at least two surgeons, anesthesiologist, coordinator, and surgical nursing staff). Therefore, the TAVI pro- 86.5% and 5-year survival: 69.4%). Subramanian et al. [18] also reported excellent outcomes of AVR in TAVI candidates
(1-year survival: 87.5% and 3-year survival: 72.7%). In this study, the mean age of the patients was 80 years, and the early and mid-term follow-up results were satisfactory. The causes for TAVI denial in these patients were 1) large annulus, 2) acceptable risk profile for AVR, 3) the need for an urgent operation, and 4) concomitant pathology that required a concomitant procedure.
The main limitation of this study was the small sample size and short follow-up duration. Because only one and a half years have passed since TAVI was first performed, a longer duration of follow-up with a larger population of randomized patients is required for more accurate comparison of the two treatment modalities.
In conclusion, TAVI is a good alternative treatment modality in inoperable or high-risk patients. However, the TAVI group had more frequent paravalvular leakage at a moderate level or higher, which can influence long-term outcomes.
AVR can be performed in old and high risk patients with good results and an acceptable level of risk. Since more and more patients are treated with TAVI even at moderate risk, careful selection of the patients and an appropriate guideline need to be established.
